TY  - JOUR
T1  - Response to Low Dose of Obeticholic Acid in Primary Biliary Cholangitis in the Real-World Population
A1  - Carina Bona
A1  - Roberto Lozano
JF  - International Journal of Pharmaceutical And Phytopharmacological Research
JO  - Int J Pharm Phytopharmacol Res
SN  - 2250-1029
Y1  - 2025
VL  - 15
IS  - 1
DO  - 10.51847/6csOnLMW3n
SP  - 1
EP  - 3
N2  - The objective of this study is to assess the real-world efficacy and safety of a 5 mg/day dose of obeticholic acid (OCA) in patients with primary biliary cholangitis (PBC). For this, a retrospective observational study was carried out. The primary endpoint was defined as alkaline phosphatase (AP) levels below the 1.67 upper limit of normal (ULN) with more than a 15% reduction from baseline, along with normal total bilirubin (TB) levels. The ‘secondary endpoint’ was the biochemical response of alanine (ALT) and aspartate (ASP) aminotransferases. The sample was composed of 26 patients who received 5 mg of OCA daily. Baseline ALP levels were below1.67 ULN in 33% of patients. After 48 months of treatment, the proportion of patients with ALP 
UR  - https://eijppr.com/article/response-to-low-dose-of-obeticholic-acid-in-primary-biliary-cholangitis-in-the-real-world-population-qbw6mnrsaikmjns
ER  -